Development and evaluation of a patient-reported outcome measure specific for Gaucher disease with or without neurological symptoms in Japan

被引:1
|
作者
Narita, Aya [1 ]
Koto, Yuta [2 ]
Noto, Shinichi [3 ]
Okada, Masafumi [4 ]
Ono, Midori [5 ]
Baba, Terumi [5 ]
Sagara, Rieko [5 ]
Sakai, Norio [6 ]
机构
[1] Tottori Univ, Div Child Neurol, Inst Neurol Sci, Fac Med, Yonago, Japan
[2] Osaka Aoyama Univ, Fac Hlth Sci, Sch Nursing, Osaka, Japan
[3] Niigata Univ Hlth & Welf, Dept Rehabil, Niigata, Japan
[4] IQVIA Solut Japan KK, Real World Evidence Solut & HEOR, Tokyo, Japan
[5] Takeda Pharmaceut Co Ltd, Japan Med Off, Tokyo, Japan
[6] Osaka Univ, Grad Sch Med, Div Hlth Sci, Child Healthcare & Genet Sci Lab, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan
关键词
Gaucher disease; Japan; Patient reported outcome measures; Quality of life; Burden of disease; Neuronopathic Gaucher disease; Reliability; Validity;
D O I
10.1186/s13023-023-02996-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Patients with Gaucher disease (GD), a rare lysosomal storage disorder, have reduced health-related quality of life (HRQOL). A patient-reported outcome measure (PROM) for HRQOL developed for type 1 GD (GD1) is not appropriate for patients with neuronopathic GD (nGD) types 2 (GD2) and 3 (GD3). In this study, we developed a new PROM for use in all GD types. We previously reported the qualitative analysis of interviews with Japanese patients with nGD, which was used to create nGD-specific PROM items. Here we evaluated the full PROM combining the type 1 questionnaire with the new nGD-specific items.Methods Patients with confirmed GD were recruited (Association of Gaucher Disease Patients in Japan or leading doctors) for pre-testing (May 2021) or the main survey (October-December 2021). The PROM had three parts: Parts 1 and 2 were translated into Japanese from the pre-existing GD1 PROM, whereas Part 3 was newly developed. Patients (or their caregivers, where necessary) completed the PROM questionnaire on paper and returned it by mail. Mean scores were determined overall and by GD type. Inter-item correlations, content consistency (Cronbach's alpha), and test-retest reliability (Cohen's kappa; main survey only, taken 2 weeks apart) were calculated.Results Sixteen patients (three with GD1; six with GD2; seven with GD3) and 33 patients (nine with GD1; 13 with GD2; 11 with GD3) participated in the pre-test and main survey, respectively. All GD2 patients and one-third (6/18) of GD3 patients required caregivers to complete the questionnaire. Mean scores indicated that the burden was highest in GD2 and lowest in GD1. In the main survey, internal consistency was high (Cronbach's alpha = 0.898 overall, 0.916 for Part 3), and test-retest reliability was high for Part 3 (kappa > 0.60 for 13/16 items) but low for Part 1 (kappa < 0.60 for 12/15 items).Conclusions We have developed a flexible and reliable PROM that can be tailored for use in all types of GD and propose using Parts 1 and 2 for GD1, Parts 2 and 3 for GD2, and Parts 1, 2, and 3 for GD3.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Development and evaluation of a patient-reported outcome measure specific for Gaucher disease with or without neurological symptoms in Japan
    Aya Narita
    Yuta Koto
    Shinichi Noto
    Masafumi Okada
    Midori Ono
    Terumi Baba
    Rieko Sagara
    Norio Sakai
    Orphanet Journal of Rare Diseases, 19
  • [2] DEVELOPMENT AND EVALUATION OF GAUCHER DISEASE-SPECIFIC PATIENT REPORTED OUTCOME MEASUREMENT IN JAPAN
    Ono, M.
    VALUE IN HEALTH, 2022, 25 (12) : S391 - S391
  • [3] Development and evaluation of Gaucher disease-specific patient reported outcome measurement in Japan
    Narita, Aya
    Koto, Yuta
    Noto, Shinichi
    Okada, Masafumi
    Ono, Midori
    Sagara, Rieko
    Sakai, Norio
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 93 - 93
  • [4] Development and evaluation of a measure of patient-reported symptoms of Blepharitis
    Hosseini, Kamran
    Bourque, Linda B.
    Hays, Ron D.
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2018, 16
  • [5] Development and evaluation of a measure of patient-reported symptoms of Blepharitis
    Kamran Hosseini
    Linda B. Bourque
    Ron D. Hays
    Health and Quality of Life Outcomes, 16
  • [6] DEVELOPMENT OF A PATIENT-REPORTED OUTCOME MEASURE IN WILSON DISEASE
    Dress, A.
    Theadorm-Oklota, C.
    Malkos, B.
    Egan, S.
    Umakanth, S.
    Evans, C.
    VALUE IN HEALTH, 2022, 25 (12) : S402 - S402
  • [7] Development of a Cold Agglutinin Disease-Specific Patient-Reported Outcome Symptom Measure
    Joly, Florence
    Dasmahapatra, Pronabesh
    Su, Jun
    Di Benedetti, Dana
    Kosa, Katherina
    Hill, Quentin
    BLOOD, 2021, 138
  • [8] DEVELOPMENT OF A PATIENT-REPORTED OUTCOME MEASURE FOR URETERAL STRICTURE DISEASE
    Boehm, Devin
    Nolla, Kyle
    Rosenfeld, Jonathan
    Ji, Emily
    Arteaga, Rebecca
    Raikar, Aidan
    Kim, Jaewoo
    Griffith, James W.
    Lee, Ziho
    JOURNAL OF UROLOGY, 2024, 211 (05): : E906 - E906
  • [9] The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease
    Asha Hareendran
    Andrew C Palsgrove
    Michelle Mocarski
    Michael L Schaefer
    Juliana Setyawan
    Robyn Carson
    Barry Make
    Health and Quality of Life Outcomes, 11
  • [10] The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease
    Hareendran, Asha
    Palsgrove, Andrew C.
    Mocarski, Michelle
    Schaefer, Michael L.
    Setyawan, Juliana
    Carson, Robyn
    Make, Barry
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2013, 11